Search PubMed⌕ Search

PubMed · 12868625

Multispectral processing without spectra.

Abstract

It is often the case that multiplications of whole spectra, component by component, must be carried out,for example when light reflects from or is transmitted through materials. This leads to particularly taxing calculations, especially in spectrally based ray tracing or radiosity in graphics, making a full-spectrum method prohibitively expensive. Nevertheless, using full spectra is attractive because of the many important phenomena that can be modeled only by using all the physics at hand. We apply to the task of spectral multiplication a method previously used in modeling RGB-based light propagation. We show that we can often multiply spectra without carrying out spectral multiplication. In previous work [J. Opt. Soc. Am. A 11, 1553 (1994)] we developed a method called spectral sharpening, which took camera RGBs to a special sharp basis that was designed to render illuminant change simple to model. Specifically, in the new basis, one can effectively model illuminant change by using a diagonal matrix rather than the 3 x 3 linear transform that results from a three-component finite-dimensional model [G. Healey and D. Slater, J. Opt. Soc. Am. A 11, 3003 (1994)]. We apply this idea of sharpening to the set of principal components vectors derived from a representative set of spectra that might reasonably be encountered in a given application. With respect to the sharp spectral basis, we show that spectral multiplications can be modeled as the multiplication of the basis coefficients. These new product coefficients applied to the sharp basis serve to accurately reconstruct the spectral product. Although the method is quite general, we show how to use spectral modeling by taking advantage of metameric surfaces, ones that match under one light but not another, for tasks such as volume rendering. The use of metamers allows a user to pick out or merge different volume structures in real time simply by changing the lighting.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Mark S Drew, Graham D Finlayson. 2003. Multispectral processing without spectra.. https://doi.org/10.1364/josaa.20.001181

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗